RECURRENT OSTEOSARCOMA
Clinical trials for RECURRENT OSTEOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OSTEOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT OSTEOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for young cancer patients: experimental drug targets recurrent tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo aims to control aggressive bone cancer in young patients
Disease control Recruiting nowThis study tests two drugs, atezolizumab and cabozantinib, in 40 adolescents and young adults (ages 12 and up) with osteosarcoma that has come back or spread. Atezolizumab helps the immune system attack cancer cells, while cabozantinib blocks enzymes that help tumors grow. The go…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Engineered immune cells take on tough bone cancer in first human test
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy called FH-FOLR1 ST CAR T-cells for people with advanced osteosarcoma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in a lab to recogniz…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC